Navigation Links
InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Date:2/17/2010

8-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 57121282.  A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 57121282.  The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY) and a New Drug Application (NDA) has been accepted for Priority Review by the FDA.  The hepatology portfolio includes the HCV protease inhibitor compound RG7227 (ITMN-191) that entered Phase 2b in August 2009 and a second-generation HCV protease inhibitor research program.  For additional information about InterMune and its R&D pipeline, please visit

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Bluegrass Vascular ... focused on innovating lifesaving devices and methods for ... Dr. Gabriele Niederauer , a seasoned senior ... the recent closure of Series A financing, BVT ... Surfacer™ Inside-Out Access Catheter System, a proprietary system ...
(Date:9/2/2014)... 2014  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... company focused on developing products to treat ... unmet medical need, as well as developing ... promising preliminary results from a preclinical study ... a non-human primate (NHP) lethal aerosol exposure ...
(Date:9/2/2014)... Sept. 2, 2014  Sinovac Biotech Ltd. (NASDAQ: ... China , today announced that the Company,s management ... , Morgan Stanley Global Healthcare Conference, to be held ... 10, 2014. , Morgan Stanley Asia Pacific Healthcare Day, ... 11, 2014. , Aegis Healthcare & Technology Conference, to ...
Breaking Medicine Technology:Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO 2Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 2Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 3Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 4Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 5Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 6Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 7Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 8Sinovac to Participate in Upcoming Investor Conferences 2
... Nov. 21, 2011   Switzerland-based Ferring Pharmaceuticals today ... Interpace Parkway in Parsippany, N.J.  The new facility will ... expansion is expected to generate jobs in the New ... The U.S. Operations Center will be a ...
... a leader in developing minimally invasive medical devices used ... the gastrointestinal tract, announces today that they have signed ... is a leading global provider of healthcare products and ... Covidien will acquire all of the outstanding capital ...
Cached Medicine Technology:Ferring Pharmaceuticals To Develop Major Corporate Center in Parsippany, New Jersey 2BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 2BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 3
(Date:9/2/2014)... (HealthDay News) -- The quality of Americans, diets has ... between the rich and poor is growing, a new ... evidence to date that the extensive efforts by many ... having some payoff, but it also indicates that these ... a doctoral student in the department of nutrition at ...
(Date:9/2/2014)... 2014 (HealthDay News) -- When it comes to excess pounds ... a new study finds. The research found that belly ... odds for high blood pressure more than overall body fat. ... high blood pressure. But it wasn,t clear how the location ... researchers at University of Texas Southwestern Medical Center in Dallas. ...
(Date:9/2/2014)... 02, 2014 North America Resectoscopes ... Market Outlook to 2020? provides key market data ... provides value, in millions of US dollars, volume ... within market segments –,     Rigid ... Reusable) Electrodes and Bipolar (Disposable and Reusable) Electrodes). ...
(Date:9/2/2014)... 02, 2014 USARAD Holdings Inc. ... telemedicine solutions provider, including SecondOpinions.com® – consumer division ... technologically advanced services. The telemedicine industry pioneer is ... Kuwait. , Founded and established in 1963 as ... Shifa began as a maternity care hospital with ...
(Date:9/2/2014)... 02, 2014 A little bit of ... sometimes the onset of irritability, sadness, or apathy can ... September 2014 Harvard Health Letter. , "Mood-related ... stresses. If they occur for long periods, cause significant ... to seek help," says Dr. Nancy Donovan, an instructor ...
Breaking Medicine News(10 mins):Health News:Quality of U.S. Diet Improves, Slightly 2Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 3Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 4Health News:When a Mood Swing Signals Trouble, From the September 2014 Harvard Health Letter 2
... 5 SectorWatch.biz announces the,availability of MarketStats for ... message boards relative to the healthy food market.,MarketStats ... the,opportunity for investors to respond with articles and ... by visiting: http://www.SectorWatch.biz ,-a division of FiSpace.net, ...
... a major website re-design, aimed specifically toward potential clients, with ... ... New York, NY (PRWEB) August 5, 2008 ... website re-design, aimed specifically toward potential clients, with improved navigability, ...
... and genetic profiling is proving many skeptics wrong. A recent ... privacy concerns. From dating, through genealogy, to preventative heart medication, ... decisions is gaining acceptance. , ... Carlsbad, Calif. (PRWEB) ...
... Properties, Inc. (NYSE: NHP ) announced today the ... to its Board of Directors. "Jeff,and Rick are remarkably ... D. Miller, NHP,s Chairman of the Board. "We look,forward ... maintain,its reputation for delivering excellent shareholder value.", Dr. ...
... to Recruit and Retain Top Notch Hospital Employees, ... Virginia Hospital Center, Arlington County,s newest child care,program, has ... by Bright Horizons Family Solutions, this center is for ... live or work in,Arlington County., Child Care & ...
... participate in fewer sports but watch less TV , , ... United States are less active and less likely to participate ... , They analyzed data from the 2003 National Survey of ... U.S. children were inactive, while 73.5 percent were physically active ...
Cached Medicine News:Health News:SectorWatch.biz Issues MarketStats for Healthy and Organic Companies ORGC, DF, WFMI, LWAY, COIN, and TOF 2Health News:Re-Designed Legal Website Includes Blog 2Health News:DNA Testing and Genetic Profiles Help Avoid Broken Hearts Polls Reveal 2Health News:DNA Testing and Genetic Profiles Help Avoid Broken Hearts Polls Reveal 3Health News:Dr. Jeffrey Rush and Richard Gilchrist Join NHP Board of Directors 2Health News:Dr. Jeffrey Rush and Richard Gilchrist Join NHP Board of Directors 3Health News:Dr. Jeffrey Rush and Richard Gilchrist Join NHP Board of Directors 4Health News:Virginia Hospital Center Opens Child Care Center for Employees and Community 2Health News:Virginia Hospital Center Opens Child Care Center for Employees and Community 3Health News:Immigrant Children Less Likely to Exercise 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: